176
Participants
Start Date
February 16, 2022
Primary Completion Date
December 31, 2026
Study Completion Date
July 31, 2028
Guselkumab
Guselkumab 100 mg 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (month 0 to month 24 for arm 1; week 24 to month 24 for arm 2).
Placebo
• Placebo to Guselkumab 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (Month 0 to Week 20 for Arm 2).
RECRUITING
NYU Langone Health, New York
RECRUITING
University of Rochester Medical Center (URMC), Rochester
RECRUITING
Brigham and Women's Hospital, Boston
RECRUITING
Memorial University, St. John's
RECRUITING
Women's College Research Institute, University of Toronto, Toronto
Janssen Scientific Affairs, LLC
INDUSTRY
NYU Langone Health
OTHER